I4T-MC-JVCY - ClinicalTrials.gov - NCT02411448
I4T-MC-JVCY - ClinicalTrials.gov - NCT02411448
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have diagnosis of Stage IV NSCLC
Participant must have documented evidence of a tumor with an activating EGFR mutation and be eligible for first-line treatment with erlotinib
Participant must be able to provide adequate archived Stage IV NSCLC tissue sample or tissue samples other than Stage IV NSCLC may be acceptable (optional for part C)
Participant must have ECOG performance status of 0 or 1 where 0 = Fully active, able to carry on all pre-disease performance without restriction and 1 = Restricted in physically strenuous activity but able to walk and carry out light work, e.g., light house work, office work
Participant must have one measurable lesion
Participants must NOT
Participant must not have a known T790M mutation
Participant must not have brain metastases
Participant must not have a history of significant bleeding disorders or blood clots in the arteries
Participant must not have any known significant abnormalities of the surface of the eye
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
Could I receive a Placebo?
yes
Enrollment Goal
562
Trial Dates
May 2015 - May 2024
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have diagnosis of Stage IV NSCLC
Participant must have documented evidence of a tumor with an activating EGFR mutation and be eligible for first-line treatment with erlotinib
Participant must be able to provide adequate archived Stage IV NSCLC tissue sample or tissue samples other than Stage IV NSCLC may be acceptable (optional for part C)
Participant must have ECOG performance status of 0 or 1 where 0 = Fully active, able to carry on all pre-disease performance without restriction and 1 = Restricted in physically strenuous activity but able to walk and carry out light work, e.g., light house work, office work
Participant must have one measurable lesion
Participants must NOT
Participant must not have a known T790M mutation
Participant must not have brain metastases
Participant must not have a history of significant bleeding disorders or blood clots in the arteries
Participant must not have any known significant abnormalities of the surface of the eye
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
Could I receive a Placebo?
yes
Enrollment Goal
562
Trial Dates
May 2015 - May 2024
Trial Phase
3
Trial Locations
Hide locations not currently recruiting